Personal cancer risk testing using genetic, blood, and tumor monitoring
Official title: A Platform for Assessing Personal Risk of Developing or Recurring of Cancer: Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring of Subclinical Recurrences With Therapeutic Impact
Run by Fondazione del Piemonte per l'Oncologia · NCT07469709 · Data updated 2026-11-12
This project will test whether combining genetic testing, blood-based analyses, and tumor tissue checks can identify personal cancer risk and detect early recurrence in adults with breast, ovarian, colorectal, melanoma, or certain non-small cell lung cancers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 850 (estimated) |
| Sponsor | Fondazione del Piemonte per l'Oncologia Academic / other |
| Locations | 1 site (Candiolo, Turin) |
| Status | Recruiting |
| Started | February 1, 2024 |
| Main results expected | May 1, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | March 13, 2026 |
| Trial ID | NCT07469709 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (over 18) with breast cancer (including those meeting AIOM/BRCA testing criteria), radically resected colon cancer, ovarian carcinoma, metastatic melanoma, or stage IIB/IIIA non-small cell lung cancer who can provide consent and samples are the intended participants.
✕Probably not a fit
People under 18, those unwilling or unable to give informed consent, and patients without the listed tumor types or who cannot provide required blood or tissue samples are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
PRO-ACTIVE is an observational program combining retrospective and prospective cohorts to build a clinical-translational prevention and early-detection pathway. The retrospective arm analyzes 400 archived breast tumor samples (200 hereditary, 200 non-hereditary) with immunohistochemistry to study angiogenesis, stromal cells, and immune infiltrates and correlate these features with prognosis. The prospective arm will enroll about 600 patients (200 each with breast, ovarian, and colorectal cancer) offered germline genetic testing and will collect blood for DNA/RNA extraction and integrated molecular profiling. Four work packages link germline DNA-RNA analysis, host/tumor molecular profiling, immune-status characterization, and tumor microenvironment study to predict personal risk and detect subclinical recurrence.
Why it matters
Potential benefit: If successful, this approach could enable earlier detection of cancer or recurrence and allow prevention or monitoring strategies tailored to each patient’s genetic and molecular profile.
How similar studies have gone: Individual elements like germline BRCA testing, liquid-biopsy approaches, and tumor microenvironment analyses have shown promise, but integrating these components into a comprehensive prevention and early-monitoring program is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 years; * Patients with breast cancer, including patients who meet the AIOM criteria for eligibility for BRCA testing and patients with lobular breast cancer; * Patients with radically resected colon cancer, including patients with stage III colon cancer and vascular invasion; * Patients with ovarian carcinomas; * Patients with metastatic melanoma; * Patients with stage IIB and IIIA non-small cell lung cancer. Exclusion Criteria: * Age \<18 years; * Unwillingness or inability to give informed consent
Where it's running
-
Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
Candiolo, Turin, Italy Recruiting
Study contacts
- Study coordinator: Vanesa Gregorc, MD
- Email: vanesa.gregorc@ircc.it
- Phone: +390119933915
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors
This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.
-
Navigation program for young cancer survivors
This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
-
Infusion of checkpoint inhibitors and chemotherapy for advanced solid tumors
This study is testing if giving a mix of immune therapy and chemotherapy directly to tumors helps people with advanced cancers feel better compared to the usual way of giving these treatments.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.